4.00
price down icon3.61%   -0.15
after-market After Hours: 4.02 0.02 +0.50%
loading
Aquestive Therapeutics Inc stock is traded at $4.00, with a volume of 881.11K. It is down -3.61% in the last 24 hours and up +23.08% over the past month. Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.15
Open:
$4.16
24h Volume:
881.11K
Relative Volume:
0.60
Market Cap:
$397.31M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-10.99
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
-5.44%
1M Performance:
+23.08%
6M Performance:
+27.39%
1Y Performance:
+4.71%
1-Day Range:
Value
$3.95
$4.17
1-Week Range:
Value
$3.95
$4.3199
52-Week Range:
Value
$2.12
$5.80

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Name
Name
Aquestive Therapeutics Inc
Name
Phone
908-941-1900
Name
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Name
Employee
142
Name
Twitter
Name
Next Earnings Date
2025-03-05
Name
Latest SEC Filings
Name
AQST's Discussions on Twitter

Compare AQST with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
AQST
Aquestive Therapeutics Inc
4.00 412.21M 58.36M -25.72M -24.91M -0.3641
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
150.75 67.73B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.31 45.73B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.70 44.38B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.51 18.97B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
298.14 13.73B 2.99B 1.21B 1.13B 25.06

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-02-25 Resumed Oppenheimer Outperform
Dec-17-24 Initiated Cantor Fitzgerald Overweight
May-10-24 Initiated Leerink Partners Outperform
Apr-11-24 Initiated Piper Sandler Overweight
Mar-28-24 Initiated Raymond James Outperform
Apr-07-21 Resumed RBC Capital Mkts Outperform
Apr-22-19 Initiated H.C. Wainwright Buy
Jan-03-19 Initiated Lake Street Buy
Aug-20-18 Initiated JMP Securities Mkt Outperform
Aug-20-18 Initiated RBC Capital Mkts Outperform
View All

Aquestive Therapeutics Inc Stock (AQST) Latest News

pulisher
12:39 PM

Is Aquestive Therapeutics Inc. a growth stock or a value stockSmart Portfolio Recommendation For Beginners - jammulinksnews.com

12:39 PM
pulisher
04:21 AM

What makes Aquestive Therapeutics Inc. stock price move sharplyBreakout Stocks Tips For Beginners - jammulinksnews.com

04:21 AM
pulisher
12:49 PM

How does Aquestive Therapeutics Inc. generate profit in a changing economyOutperformance with explosive growth - jammulinksnews.com

12:49 PM
pulisher
Jul 27, 2025

Should I hold or sell Aquestive Therapeutics Inc. stock in 2025Maximize gains with strategic stock entries - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Aquestive Therapeutics Inc.Rapid market gains - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the technical indicators suggesting about Aquestive Therapeutics Inc.Unprecedented profit potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What institutional investors are buying Aquestive Therapeutics Inc. stockRemarkably fast returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How Efficient Is Aquestive Therapeutics Inc. at Controlling Operating CostsBreakout Confirmation Tool - Metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

What is the dividend policy of Aquestive Therapeutics Inc. stockUnlock powerful portfolio optimization tools - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How strong is Aquestive Therapeutics Inc. company’s balance sheetAccelerated investment success - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Why Aquestive Therapeutics Inc. stock attracts strong analyst attentionFree VIP Group - Metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Is Aquestive Therapeutics Inc. a good long term investmentExceptional stock performance - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Aquestive Therapeutics Inc. stock priceDynamic growth stocks - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Aquestive Therapeutics Inc. stock outlookTremendous gains - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Why Aquestive Therapeutics Inc. stock is on top investor watchlistsDynamic capital growth - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Should I buy Aquestive Therapeutics Inc. stock before earningsRapidly growing investment returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Aquestive Therapeutics Inc. Stock Analysis and ForecastBreakthrough investment results - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 22, 2025

What analysts say about Aquestive Therapeutics Inc. stockAccelerated profit realization - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer - Stock Titan

Jul 22, 2025
pulisher
Jul 21, 2025

After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar - simplywall.st

Jul 21, 2025
pulisher
Jul 21, 2025

Aquestive's Anaphylm to be reviewed by Health Canada - MSN

Jul 21, 2025

Aquestive Therapeutics Inc Stock (AQST) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$72.41
price down icon 0.71%
$14.58
price down icon 2.28%
$9.26
price down icon 1.59%
drug_manufacturers_specialty_generic RDY
$14.70
price up icon 0.20%
$133.71
price up icon 1.19%
$298.14
price down icon 2.09%
Cap:     |  Volume (24h):